Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?

El Hiperparatiroidismo primario (HPTP) es un trastorno endocrino frecuente caracterizado por una secreción autónoma de hormona paratiroidea (PTH). Si bien, su variante asintomática es la más frecuentemente encontrada en la práctica clínica (la cual se diagnostica incidentalmente), las complicaciones...

Full description

Autores:
Rojas, Joselyn
Olivar, Luis Carlos
Chávez Castillo, Mervin
Martínez, María Sofia
Wilches-Durán, Sandra
Tipo de recurso:
Fecha de publicación:
2017
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
spa
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/1850
Acceso en línea:
http://hdl.handle.net/20.500.12442/1850
Palabra clave:
Hiperparatirodismo primario
Aldosterona
Hormona paratiroidea
Hipertensión arterial
Riesgo cardiovascular
Mortalidad cardiovascular
Primary Hiperparathyroidism
Aldosterone
Parathyroid hormone
Hypertension
Cardiovascular risk
Cardiovascular mortality
Rights
License
Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
id USIMONBOL2_a4abd740968a901b9576e1366c68f866
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/1850
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.spa.fl_str_mv Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
title Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
spellingShingle Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
Hiperparatirodismo primario
Aldosterona
Hormona paratiroidea
Hipertensión arterial
Riesgo cardiovascular
Mortalidad cardiovascular
Primary Hiperparathyroidism
Aldosterone
Parathyroid hormone
Hypertension
Cardiovascular risk
Cardiovascular mortality
title_short Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
title_full Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
title_fullStr Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
title_full_unstemmed Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
title_sort Hormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?
dc.creator.fl_str_mv Rojas, Joselyn
Olivar, Luis Carlos
Chávez Castillo, Mervin
Martínez, María Sofia
Wilches-Durán, Sandra
dc.contributor.author.none.fl_str_mv Rojas, Joselyn
Olivar, Luis Carlos
Chávez Castillo, Mervin
Martínez, María Sofia
Wilches-Durán, Sandra
dc.subject.spa.fl_str_mv Hiperparatirodismo primario
Aldosterona
Hormona paratiroidea
Hipertensión arterial
Riesgo cardiovascular
Mortalidad cardiovascular
topic Hiperparatirodismo primario
Aldosterona
Hormona paratiroidea
Hipertensión arterial
Riesgo cardiovascular
Mortalidad cardiovascular
Primary Hiperparathyroidism
Aldosterone
Parathyroid hormone
Hypertension
Cardiovascular risk
Cardiovascular mortality
dc.subject.eng.fl_str_mv Primary Hiperparathyroidism
Aldosterone
Parathyroid hormone
Hypertension
Cardiovascular risk
Cardiovascular mortality
description El Hiperparatiroidismo primario (HPTP) es un trastorno endocrino frecuente caracterizado por una secreción autónoma de hormona paratiroidea (PTH). Si bien, su variante asintomática es la más frecuentemente encontrada en la práctica clínica (la cual se diagnostica incidentalmente), las complicaciones óseas y renales afectan de forma importante la calidad de vida del paciente. Sin embargo, el espectro de manifestaciones de este trastorno no se limita al metabolismo mineral, puesto que las concentraciones elevadas de PTH se asocian a un mayor riesgo de alteraciones metabólicas como el síndrome metabólico, diabetes mellitus 2 y enfermedades cardiovasculares. En este ámbito, la hipertensión arterial (HTA), relacionada con aproximadamente 9,4 millones de muerte al año, ha sido considerada una manifestación no clásica del HPTP. La interacción PTH-Aldosterona ha surgido como un importante eslabón para tratar de explicar esta relación, planteándose diversos mecanismos teóricos que posicionan a la PTH como estimulador directo de la síntesis de aldosterona en las células de la zona glomerular. Sin embargo, estos mecanismos teóricos han estado rodeados de controversia en su aspecto epidemiológico y clínico, existiendo aún muy pocos estudios poblacionales explorando este vínculo y su relación con la morbimortalidad cardiovascular, por lo que es necesario mayor investigación en el área con el fin de conocer el verdadero impacto de estos mecanismos en la salud de los individuos. Esta revisión resume aspectos del metabolismo del calcio, al igual que los principales mecanismos subyacentes al vínculo HPTP-HTA, y los datos epidemiológicos disponibles sobre el tópico, a fin de brindar un mejor entendimiento sobre este novel planteamiento.
publishDate 2017
dc.date.issued.none.fl_str_mv 2017
dc.date.accessioned.none.fl_str_mv 2018-03-12T16:23:30Z
dc.date.available.none.fl_str_mv 2018-03-12T16:23:30Z
dc.type.spa.fl_str_mv article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 18564550
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12442/1850
identifier_str_mv 18564550
url http://hdl.handle.net/20.500.12442/1850
dc.language.iso.spa.fl_str_mv spa
language spa
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
rights_invalid_str_mv Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
http://purl.org/coar/access_right/c_abf2
dc.publisher.spa.fl_str_mv Cooperativa servicios y suministros 212518 RS
dc.source.spa.fl_str_mv Revista Latinoamericana de Hipertensión
Vol. 12, No.1 (2017)
institution Universidad Simón Bolívar
dc.source.uri.none.fl_str_mv https://www.redalyc.org/articulo.oa?id=170250838001
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/b8b14705-0e14-44ab-9002-998427063171/download
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv DSpace UniSimon
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814076137150611456
spelling Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalhttp://purl.org/coar/access_right/c_abf2Rojas, Joselyn2aa91570-0516-424d-8f76-25cd7b39be6e-1Olivar, Luis Carlos212e67d1-e669-4a31-9299-d653994d03a6-1Chávez Castillo, Mervin8f5d4f42-382f-4e4d-b9d1-3b85d6e1fcd2-1Martínez, María Sofiac2c15b32-7287-4e03-a13d-63cc39b1e432-1Wilches-Durán, Sandra57727544-0054-45e6-997c-6d75c266cea0-12018-03-12T16:23:30Z2018-03-12T16:23:30Z201718564550http://hdl.handle.net/20.500.12442/1850El Hiperparatiroidismo primario (HPTP) es un trastorno endocrino frecuente caracterizado por una secreción autónoma de hormona paratiroidea (PTH). Si bien, su variante asintomática es la más frecuentemente encontrada en la práctica clínica (la cual se diagnostica incidentalmente), las complicaciones óseas y renales afectan de forma importante la calidad de vida del paciente. Sin embargo, el espectro de manifestaciones de este trastorno no se limita al metabolismo mineral, puesto que las concentraciones elevadas de PTH se asocian a un mayor riesgo de alteraciones metabólicas como el síndrome metabólico, diabetes mellitus 2 y enfermedades cardiovasculares. En este ámbito, la hipertensión arterial (HTA), relacionada con aproximadamente 9,4 millones de muerte al año, ha sido considerada una manifestación no clásica del HPTP. La interacción PTH-Aldosterona ha surgido como un importante eslabón para tratar de explicar esta relación, planteándose diversos mecanismos teóricos que posicionan a la PTH como estimulador directo de la síntesis de aldosterona en las células de la zona glomerular. Sin embargo, estos mecanismos teóricos han estado rodeados de controversia en su aspecto epidemiológico y clínico, existiendo aún muy pocos estudios poblacionales explorando este vínculo y su relación con la morbimortalidad cardiovascular, por lo que es necesario mayor investigación en el área con el fin de conocer el verdadero impacto de estos mecanismos en la salud de los individuos. Esta revisión resume aspectos del metabolismo del calcio, al igual que los principales mecanismos subyacentes al vínculo HPTP-HTA, y los datos epidemiológicos disponibles sobre el tópico, a fin de brindar un mejor entendimiento sobre este novel planteamiento.Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by autonomic parathyroid hormone secretion (PTH). Although its asymptomatic variant is the most frequently found in clinical practice (which is incidentally diagnosed), bone and kidney complications significantly affect the patient’s quality of life. However, the spectrum of manifestations of this disorder is not limited to mineral metabolism, since elevated concentrations of PTH are associated with an increased risk of metabolic syndrome, type 2 diabetes mellitus and cardiovascular disease. In this area, hypertension (AHT), related to approximately 9.4 million deaths per year, has been considered a non-classical manifestation of PHPT. The interaction PTH-Aldosterone has emerged as an important link to try to explain this relationship, posing various theoretical mechanisms that position PTH as a direct stimulator of aldosterone synthesis in the glomerular zone cells. However, these theoretical mechanisms have been surrounded by controversy in their epidemiological and clinical aspects, and there are still very few population studies exploring this link and its relation with cardiovascular morbimortality, which is why more research is needed in the area in order to know. The true impact of these mechanisms on the health of individuals. This review summarizes aspects of calcium metabolism, as well as the main mechanisms underlying the HPTP-HTA link, and available epidemiological data on the topic, in order to provide a better understanding of this novel approach.spaCooperativa servicios y suministros 212518 RSRevista Latinoamericana de HipertensiónVol. 12, No.1 (2017)https://www.redalyc.org/articulo.oa?id=170250838001Hiperparatirodismo primarioAldosteronaHormona paratiroideaHipertensión arterialRiesgo cardiovascularMortalidad cardiovascularPrimary HiperparathyroidismAldosteroneParathyroid hormoneHypertensionCardiovascular riskCardiovascular mortalityHormona paratiroidea, aldosterona e hipertensión arterial ¿una amenaza infravalorada?articlehttp://purl.org/coar/resource_type/c_6501WHO. The top ten causes of death. Fact sheet No 310 / May 2014 Avalaible at: http://www. who.int/mediacentre/factsheets/fs310/en/.Who. Global status report on noncommunicable diseases 2014. Available at: http://apps.who. int/iris/bitstream/10665/148114/1/9789241564854_eng.pdfLim SS, Vos T, Flaxman AD, Danaei G, et al A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2224-60.Velasco A, Vongpatanasin W. The evaluation and treatment of endocrine forms of hypertension. Curr Cardiol Rep. 2014;16(9):528.Richert L, Trombetti A, Herrmann FR, Triponez F, Meier C, Robert JH, Rizzoli R. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly. 2009;139(27-28):400-4.Cordellat IM. Hiperparatiroidismo: ¿primario o secundario?. Reumatol Clin. 2012;8(5):287– 291Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991t;6 Suppl 2:S51-9; discussion S61.Makras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones (Athens). 2009;8(2):83-95.Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171-7.Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17 Suppl 2:N12-7.Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10):3561-9.Orlov SN, Aksentsev SL, Kotelevtsev SV. Extracellular calcium is required for the maintenance of plasma membrane integrity in nucleated cells. Cell Calcium. 2005 Jul;38(1):53-7.Ozkul Y. Influence of calcium channel blocker drugs in neuromuscular transmission. Clin Neurophysiol. 2007;118(9):2005-8.Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc). 2002;67(1):3-12Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29.Wang L, Nancollas GH, Henneman ZJ: Nanosized particles in bone and dissolution insensitivity of bone mineral. Biointerphases 1: 106 –111, 2006.Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc. 2002;4(4):301-6.Peacock M. Calcium Metabolism in Health and Disease. Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S23-30.Goswami R, Mohapatra T, Gupta N, Rani R, Tomar N, Dikshit A, Sharma RK. P arathyroid hormone gene polymorphism and sporadic idiopathic hypoparathyroidism. J Clin Endocrinol Metab. 2004;89(10):4840-5.Jüppner, H, Gardella, TJ, Brown, EM, et al: Parathyroid hormone, and parathyroid hormonerelated peptide in the regulation of calcium homeostasis and bone development (chapt 70), in Endocrinology (2001, vol 2, 4th ed) edited by DeGroot LJ, Jameson JL, Philadelphia, W.B. Saunders Co., pp 969–998.Goodman WG, Jüppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. 2003 Jan;63(1):1-11.Tanaka M, Komaba H, Itoh K, et al. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus. 2008;1(Suppl 3):iii59-iii62.Zhang Z, Sun S, Quinn SJ, Brown EM, Bai M. The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions. J Biol Chem. 2001 Feb 16;276(7):5316-22Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011 Feb;22(2):216-24.Quitterer U, Hoffmann M, Freichel M, Lohse MJ. Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J Biol Chem. 2001 Mar 2;276(9):6763-9.Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci. 2011 Jan;68(1):1- 13.Greenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8(10):1163-71.Efrati E, Arsentiev-Rozenfeld J, Zelikovic I. The human paracellin-1 gene (hPCLN-1): renal epithelial cell-specific expression and regulation. Am J Physiol Renal Physiol 2005;288:F272-F283.Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: an evidence-based review. J Am Board Fam Med. 2009 (6):698-706.Jones G, Byford V, West S, et al. Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res2006;26:2.Hemmingsen C. Regulation of renal calbindin-D28K. Pharmacol Toxicol. 2000;87 Suppl 3:5-30.Bikle DD. Vitamin D and bone. Curr Osteoporos Rep. 2012;10(2):151-9.Davey RA, Findlay DM. Calcitonin: Physiology or Fantasy?. J Bone Miner Res. 2013 May;28(5):973-9.Shinki T, Ueno Y, DeLuca HF, Suda T. Calcitonin is a major regulator for the expression of renal 25‐hydroxyvitamin D3‐1alpha‐hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A. 1999 Jul;96(14):8253–8Kawashima H, Torikai S, Kurokawa K. Calcitonin selectively stimulates 25‐hydroxyvitamin D3‐1 alpha‐hydroxylase in proximal straight tubule of rat kidney. Nature. 1981;291(5813):327–9.Zhang Z, Neff L, Bothwell AL, Baron R, Horne WC. Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone. 2002;31(3):359–65.Moonga BS, Moss DW, Patchell A, Zaidi M. Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption. J Physiol. 1990;429:29–45.Mancini L, Moradi‐Bidhendi N, Brandi ML, Perretti M, MacIntyre I. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Commun. 2000;279(2):391–7.Urruticoechea-Arana A, Martín-Martínez MA, Castañeda S, Piedra CA, González-Juanatey C, Llorca J, Díaz-Gonzalez F, González-Gay MA; CARMA Project Collaborative Group. Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. Arthritis Res Ther. 2015;17:211.Bilir B, Tulubas F, Bilir BE, Atile NS, Kara SP, Yildirim T, Gumustas SA, Topcu B, Kaymaz O, Aydin M. The association of vitamin D with inflammatory cytokines in diabetic peripheral neuropathy. J Phys Ther Sci. 2016;28(7):2159-63.oergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care. 2010;33(10):2238-43.Lang CL, Wang MH, Chiang CKK, Lu KC. Vitamin D and the Immune System from the Nephrologist’s Viewpoint. ISRN Endocrinology. 2014:2014105456.Aggarwal R, Akhthar T, Jain SK. Coronary artery disease and its association with Vitamin D deficiency. J Midlife Health. 2016;7(2):56-60.Syal SK, Kapoor A, Bhatia E, Sinha A, Kumar S, Tewari S, Garg N, Goel PK. Vitamin D deficiency, coronary artery disease, and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J Invasive Cardiol. 2012;24(8):385-9.Dressler N, Chandra A, Aguirre Dávila L, Spineli LM, Schippert C, von Versen-Höynck F. BMI and season are associated with vitamin D deficiency in women with impaired fertility: a two-centre analysis. Arch Gynecol Obstet. 2016 Apr;293(4):907-14.Dabrowski FA, Grzechocinska B, Wielgos M. The role of vitamin D in reproductive health--a Trojan Horse or the Golden Fleece? Nutrients. 2015;7(6):4139-53.Sowell KD, Keen CL, Uriu-Adams JY. Vitamin D and Reproduction: From Gametes to Childhood. Healthcare (Basel). 2015;3(4):1097-120.Neupane SP, Lien L, Hilberg T, Bramness JG. Vitamin D deficiency in alcohol-use disorders and its relationship to comorbid major depression: a cross-sectional study of inpatients in Nepal. Drug Alcohol Depend. 2013;133(2):480-5.Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013;202:100-7.Guo Y, Li Z, Ding R, Li H, Zhang L, Yuan W, Wang Y. Parathyroid hormone induces epithelialto- mesenchymal transition via the Wnt/β-catenin signaling pathway in human renal proximal tubular cells. Int J Clin Exp Pathol. 2014;7(9):5978-87.Abdallah Sassine Geara, Mario R. Castellanos, Claude Bassil, Georgia Schuller-Levis, Eunkue Park, Marianne Smith, Michael Goldman, and Suzanne Elsayegh. Effects of Parathyroid Hormone on Immune Function. Clinical and Developmental Immunology. 2010;2010418695.Perkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG, Becker GJ. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res. 2003;26(1):27-33.Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone- related peptide. Cardiovasc Res. 1998;37(1):34-41.Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A. Human interventions to characterize novel relationships between the reninangiotensin- aldosterone system and parathyroid hormone. Hypertension. 2014;63(2):273-80.Jiang B, Morimoto S, Yang J, Niinoabu T, Fukuo K, Ogihara T. Expression of parathyroid hormone/ parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S142-4.Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrino. 1987;112(3):431-7.Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9-20.Sharma J, Itum DS, Moss L, Chun-Li C, Weber C. Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism. World J Surg. 2014;38(6):1268-73.Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, Brown JP, Goltzman D; the CaMos Research Group. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2014 Jul 25.Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-94.AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11(1):49- 54.Twigt BA, Scholten A, Valk GD, Rinkes IH, Vriens MR. Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis. 2013;8:50.Takami H, Shirahama S, Ikeda Y, Sasaki Y, Wada N, Niimi M, Kameyama K. Familial hyperparathyroidism. Biomed Pharmacother. 2000;54 Suppl 1:21s-24s.Pepe J, Cipriani C, Pilotto R, De Lucia F, Castro C, Lenge L, Russo S, Guarnieri V, Scillitani A, Carnevale V, D’Erasmo E, Romagnoli E, Minisola S. Sporadic and hereditary primary hyperparathyroidism. J Endocrinol Invest. 201;34(7 Suppl):40-4.Albright F, Reifenstein EC. The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins; 1984. pp. 145–204.Ghada El-Hajj Fuleihan. Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms?. J Clin Endocrinol Metab. September 2008, 93(9):3302–3304.Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A. Role of vitamin D and nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002;17:N75–80.Kollars J, Zarroug AE, van Heerden J, Lteif A, Stavlo P, Suarez L, Moir C, Ishitani M, Rodeberg D. Primary hyperparathyroidism in pediatric patients. Pediatrics. 2005;115(4):974-80.Broulík P, Adámek S, Libánský P, Kubinyi J. Changes in the Pattern of Primary Hyperparathyroidism in Czech Republic. Prague Med Rep. 2015;116(2):112-21.Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, Schwarz J, Seibel MJ. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004; 89: 5477–5481.Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119(21):2765-71.Pilz S1, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31(13):1591-8.Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30(5):606-20.Pirro M, Manfredelli MR, Helou RS, Scarponi AM, Schillaci G, Bagaglia F, Melis F, Mannarino E. Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency. J Atheroscler Thromb. 2012;19:924–931.Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol. 2007; 292: F1215–F1218.Amann K, Tornig J, Flechtenmacher C, Nabokov A, Mall G, Ritz E. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant. 1995; 10: 2043–2048.Rosenthal FD, Roy S. Hypertension and Hyperparathyroidism. Br Med J. 1972; 4(5837): 396– 397.Eufrazino C, Veras A, Bandeira F. Epidemiology of Primary Hyperparathyroidism and its Nonclassical Manifestations in the City of Recife, Brazil. Clin Med Insights Endocrinol Diabetes. 2013;6:69-74.Madhavan T, Frame B, Block MA. Influence of surgical correction of primary hyperparathyroidism on associated hypertension. Arch Surg. 1970;100(2):212-4.Feldstein CA, Akopian M, Pietrobelli D, Olivieri A, Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clin Exp Hypertens. 2010;32(3):154-8.Luigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C, Luciano C, Giuseppe P, Sabrina C, Susanna S, Antonio C, Giuseppe C, Giorgio de T, Claudio L. Arterial Hypertension, Metabolic Syndrome and Subclinical Cardiovascular Organ Damage in Patients with Asymptomatic Primary Hyperparathyroidism before and after Parathyroidectomy: Preliminary Results. Int J Endocrinol. 2012;2012:408295.Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab. 2001;280(2):E209-13.Chowdhury SD, Gray JG. Renal function and hypertension in primary hyperparathyroidism. Br J Surg. 1973;60(1):53-6.HELLSTROM J, BIRKE G, EDVALL CA. Hypertension in hyperparathyroidism. Br J Urol. 1958 Mar;30(1):13–24Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol. 2012;110(1):49-55.Ureña P, Kong XF, Abou-Samra AB, Jüppner H, Kronenberg HM, Potts JT Jr, Segre GV. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology. 1993;133(2):617-23.Kitazawa S, Fukase M, Kitazawa R, Takenaka A, Gotoh A, Fujita T, Maeda S. Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer. 1991;67(4):984-9.Lupp A, Klenk C, Röcken C, Evert M, Mawrin C, Schulz S. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol. 2010;162(5):979-86.Marotta SF. The role of parathyroid hormone and thyrocalcitonin in altering plasma calcium levels and adrenocortical secretory rates. Horm Metab Res. 1971;3(5):344-8.Lasco A, Catalano A, Morabito N, Gaudio A, Basile G, Trifiletti A, Atteritano M. Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporos Int. 2011;22(1):299-303.Betancourt-Calle S, Calle RA, Isales CM, White S, Rasmussen H, Bollag WB. Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation. Mol Cell Endocrinol. 2001;173(1-2):87-94.Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350(2):151-62.Midzak A, Rone M, Aghazadeh Y, Culty M, Papadopoulos V. Mitochondrial protein import and the genesis of steroidogenic mitochondria. Mol Cell Endocrinol. 2011;336(1-2):70-9.Miller WL. Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol. 2013;379(1-2):62- 73.Python CP, Laban OP, Rossier MF, Vallotton MB, Capponi AM. The site of action of Ca2+ in the activation of steroidogenesis: studies in Ca(2+)-clamped bovine adrenal zona-glomerulosa cells. Biochem J. 1995;305 ( Pt 2):569-76.Cherradi N, Rossier MF, Vallotton MB, Capponi AM. Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells. J Biol Chem. 1996;271(42):25971-5.Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 2007;112(8):417-28.Capponi AM, Lew PD, Jornot L, Vallotton MB. Correlation between cytosolic free Ca2+ and aldosterone production in bovine adrenal glomerulosa cells. Evidence for a difference in the mode of action of angiotensin II and potassium. J Biol Chem. 1984;259(14):8863-9.Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129(1):489-95.Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab. 1994;20(5):309-14.Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489-539.Rossier MF, Ertel EA, Vallotton MB, Capponi AM. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther. 1998;287(3):824-31.Yao J, Davies LA, Howard JD, Adney SK, Welsby PJ, Howell N, Carey RM, Colbran RJ, Barrett PQ. Molecular basis for the modulation of native T-type Ca2+ channels in vivo by Ca2+/calmodulindependent protein kinase II. J Clin Invest. 2006;116(9):2403-12.Lotshaw DP. Role of membrane depolarization and T-type Ca2+channels in angiotensin II and K+ stimulated aldosterone secretion. Mol Cell Endocrinol. 2001;175: 157–171, 2001.Balla T, Várnai P, Holló Z, Spät A. Effects of high potassium concentration and dihydropyridine Ca2(+)-channel agonists on cytoplasmic Ca2+ and aldosterone production in rat adrenal glomerulosa cells. Endocrinology. 1990;127(2):815-22.Ely JA, Ambroz C, Baukal AJ, Christensen SB, Balla T, Catt KJ. Relationship between agonistand thapsigargin-sensitive calcium pools in adrenal glomerulosa cells. Thapsigargin-induced Ca2+ mobilization and entry. J Biol Chem. 1991;266(28):18635-41.Haksar A, Péron FG. The role of calcium in the steroidogenic response of rat adrenal cells to adrenocorticotropic hormone. Biochim Biophys Acta. 1973;313(2):363-71.Hyatt PJ, Tait JF, Tait SAS. The mechanism of the effect of K+ on the steroidogenesis of rat zona glomerulosa cells of the adrenal cortex: role of cyclic AMP. Proc R Soc Lond B Biol Sci. 1986;227: 21–42.Tait JF, Tait SA. Role of AMPc in the effects of K+ on the steroidogenesis of zona glomerulosa cells. Clin Exp Pharmacol Physiol. 1999;26(12):947-55.Antoni FA. Calcium regulation of adenylyl cyclase relevance for endocrine control. Trends Endocrinol Metab. 1997;8(1):7-14.Côté M, Guillon G, Payet MD, Gallo-Payet N. Expression and regulation of adenylyl cyclase isoforms in the human adrenal gland. J Clin Endocrinol Metab. 2001;86(9):4495-503.Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186(1):1-20.Nogueira EF, Rainey W. Regulation of Aldosterone Synthase by Activator Transcription Factor/ cAMP Response Element-Binding Protein Family Members. Endocrinology. 2010; 151(3): 1060–1070.Nogueira EF, Xing Y, Morris CA, Rainey NOSOTROS. Role of angiotensin II-induced rapid response genes in the regulation of enzymes needed for aldosterone synthesis. J Mol Endocrinol 2009; 42 (4) :319-30.Pezzi V, Clyne CD, Ando S, Mathis JM, Rainey WE. Ca(2+)-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases. Endocrinology. 1997;138(2):835-8.Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol. 2012;2012:519467.Sirianni R, Nogueira E, Bassett MH, Carr BR, Suzuki T, Pezzi V, Andò S, Rainey WE. The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. J Cell Sci. 2010 Nov 15;123(Pt 22):3956-65.Hoeflich A, Bielohuby M. Mechanisms of adrenal gland growth: signal integration by extracellular signal regulated kinases1/2. J Mol Endocrinol. 2009;42(3):191-203.Miller WL, Auchus RJ.The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81-151.Schillaci G, Pucci G, Pirro M, Monacelli M, Scarponi AM, Manfredelli MR, Rondelli F, Avenia N, Mannarino E. Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis. 2011;218(1):96-101.Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic Valve Calcification in Mild Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(1): 132–137.Brown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, Vaidya A. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490-9.Saussine C, Judes C, Massfelder T, Musso MJ, Simeoni U, Hannedouche T, Helwig JJ. Stimulatory action of parathyroid hormone on renin secretion in vitro: a study using isolated rat kidney, isolated rabbit glomeruli and superfused dispersed rat juxtaglomerular cells. Clin Sci (Lond). 1993;84(1):11-9.Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, Skøtt O, Jensen BL. Regulation of renin secretion by renal juxtaglomerular cells. Pflugers Arch. 2013;465(1):25-37.Pedraza-Chaverri J, Ibarra-Rubio ME, Cruz C, Tapi E. [Intracellular messengers in the regulation of renin secretion]. [Article in Spanish]. Rev Invest Clin. 1989 Apr-Jun;41(2):165-75.Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology (Bethesda). 2007;22:310-9.Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol. 2010;298(1):F1-F11.Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Decreased intracellular calcium stimulates renin release via calcium-inhibitable adenylyl cyclase. Hypertension. 2007;49(1):162-9.Ortiz-Capisano MC, Reddy M, Mendez M, Garvin JL, Beierwaltes WH. Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor. Am J Physiol Renal Physiol. 2013;304(3):F248-56.Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. Hypertension. 2007;49(3):618-24.Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH. Hypertension. 2007;50(4):737-43.Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension. 2011;58(4):604-10.Bukoski RD, Ishibashi K, Bian K. Vascular actions of the calcium-regulating hormones. Semin Nephrol. 1995;15(6):536-49.Wang R, Karpinski E, Pang PK. Parathyroid hormone selectively inhibits L-type calcium channels in single vascular smooth muscle cells of the rat. J Physiol. 1991 Sep; 441: 325–346.Helwig JJ, Musso MJ, Judes C, Nickols GA. Parathyroid hormone and calcium: interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology. 1991;129(3):1233-42.Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18.Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300.Zennaro MC, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol. 2015;224(2):R63-77.Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord. 2007;8(4):309-20.Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331-6.Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calò LA, Frigo AC, Fassina A, Pessina AC. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. 2012;60(2):431-6.Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78(3):385-90.Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105(5):649-54.Pilz S, Tomaschitz A, März W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: a complex and clinically relevant relationship. Calcif Tissue Int. 2010 Oct;87(4):373-4.Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8(9):884-93.Kabadi UM. Renal calculi in primary hyperaldosteronism. J Postgrad Med 1995;41:17–18.Shey J, Cameron MA, Sakhaee K, Moe OW. Recurrent calcium nephrolithiasis associated with primary aldosteronism. Am J Kidney Dis. 2004;44(1):e7-12.Yasuda K, Sasaki K, Yamato M, Rakugi H, Isaka Y, Hayashi T. A case of nephrocalcinosis associated with primary aldosteronism. Intern Med. 2012;51(6):625-7Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97(1):E75-9.Laguardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332(3):112-8.Sun Y, Ahokas RA, Bhattacharya SK, Gerling IC, Carbone LD, Weber KT. Oxidative stress in aldosteronism. Cardiovascular Research. 2006;71(2):300-309.Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58(3):341-6.Leopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation. 2011;124(18):e466-8.Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between Parathyroid Hormone Levels and Inflammatory Markers among US Adults. Mediators of Inflammation. 2014;2014709024.Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related toatherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):493-8.Emam AA, Mousa SG, Ahmed KY, Al-Azab AA. Inflammatory biomarkers in patients with asymptomatic primary hyperparathyroidism. Med Princ Pract. 2012;21(3):249-53.Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307(1-2):77-82.Christensen MH, Dankel SN, Nordbø Y, Varhaug JE, Almås B, Lien EA, Mellgren G. Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLoS One. 2011;6(6):e20481.Mittendorfer B. Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking. Curr Opin Clin Nutr Metab Care. 2011;14(6):535-41.Virdis A, Santini F, Colucci R, Duranti E, Salvetti G, Rugani I, Segnani C, Anselmino M, Bernardini N, Blandizzi C, Salvetti A, Pinchera A, Taddei S. Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol. 2011;58(3):238-47.Virdis A, Duranti E, Rossi C, Dell’Agnello U, Santini E, Anselmino M, Chiarugi M, Taddei S, Solini A. Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. Eur Heart J. 2015;36(13):784- 94.Farb MG, Ganley-Leal L, Mott M, Liang Y, Ercan B, Widlansky ME, Bigornia SJ, Fiscale AJ, Apovian CM, Carmine B, Hess DT, Vita JA, Gokce N. Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol. 2012;32(2):467-73.Hafner F, Kieninger A, Meinitzer A, Gary T, Froehlich H, Haas E, Hackl G, Eller P, Brodmann M, Seinost G. Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PLoS One. 2014;9(4):e93357.Ekmekci A, Abaci N, Colak Ozbey N, Agayev A, Aksakal N, Oflaz H, Erginel-Unaltuna N, Erbil Y. Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism. J Endocrinol Invest. 2009;32(7):611-6.Kosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH, Barenbrock M. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res. 2000;47(4):813-8.Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH, Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens. 2000;13(7):759-64.Tuna MM, Doğan BA, Arduç A, Imga NN, Tütüncü Y, Berker D, Güler S. Impaired endothelial function in patients with mild primary hyperparathyroidism improves after parathyroidectomy. Clin Endocrinol (Oxf). 2015;83(6):951-6.Yilmaz BA, Toruner B, Akyel A, Ercin U, Değertekin CK, Lyidir OT, Tavil Y, Bilgihan A, Arslan M. ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM. Acta Endocrinologica (Buc). 2015;XI(4):482-488.Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111(7):871-8.Bhattacharya SK, Gandhi MS, Kamalov G, Ahokas RA, Sun Y, Gerling IC, Weber KT. Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism. Curr Hypertens Rep. 2009;11(6):412-20.Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290(1):H286-94.Yusuf J, Khan MU, Cheema Y, Bhattacharya SK, Weber KT. Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones. Prog Cardiovasc Dis. 2012;55(1):77-86.Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest. 1981; 67(4):1215–1227.Bogin E, Levi J, Harary I, Massry SG. Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. Miner Electrolyte Metab. 1982;7(3):151-6.Baczynski R, Massry SG, Kohan R, Magott M, Saglikes Y, Brautbar N. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int. 1985;27(5):718-25.Shaheen M, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer- effector pathway. Exp Clin Cardiol. 2011;16(4):109-15.Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther. 2013;27(2):161-70.Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13(1):114-9.Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161(5):1773-81.Thomas M, Vidal A, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol. 2007;293(4):H2361-6.De Marchi E, Baldassari F, Bononi A, Wieckowski MR, Pinton P. Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C. Oxid Med Cell Longev. 2013;2013:564961.Perrotta I, Aquila S. The role of oxidative stress and autophagy in atherosclerosis. Oxid Med Cell Longev. 2015;2015:130315.Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26(7):1390-4.van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, Ix JH, Visser M, Brouwer IA. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(12):1214-22.Yagi S, Aihara K, Kondo T, Endo I, Hotchi J, Ise T, Iwase T, Akaike M, Matsumoto T, Sata M. High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients. Endocr J. 2014;61(7):727-33.Lafferty FW. Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med. 1981;141(13):1761-6.Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009;146(6):1042-7.Broulik PD, Brouliková A, Adámek S, Libanský P, Tvrdoň J, Broulikova K, Kubinyi J. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol. 2011;2011:309068.Gennari C, Nami R, Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Miner Electrolyte Metab. 1995;21(1- 3):77-81.Kovács L, Góth MI, Szabolcs I, Dohán O, Ferencz A, Szilágyi G. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol. 1998 May;138(5):543-7.Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J. Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? J Clin Endocrinol Metab. 2015;100(6):2420-4.Verheyen N, Fahrleitner-Pammer A, Pieske B, Meinitzer A, Belyavskiy E, Wetzel J, Gaksch M, Grübler MR, Catena C, Sechi LA, Van Ballegooijen AJ, Brandenburg VM, Scharnagl H, Perl S, Brussee H, März W, Pilz S, Tomaschitz A. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. J Hypertens. 2016;34(9):1778- 86.Tomaschitz A, Verheyen N, Meinitzer A, Pieske B, Belyavskiy E, Brussee H, Haas J, März W, Pieske-Kraigher E, Verheyen S, Ofner-Ziegenfuss L, Hartaigh BÓ, Schwetz V, Aberer F, Grübler M, Lang F, Alesutan I, Voelkl J, Gaksch M, Horina JH, Dimai HP, Rus-Machan J, Stiegler C, Ritz E, Fahrleitner-Pammer A, Pilz S. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebocontrolled trial. J Hypertens. 2016;34(7):1347-56.Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery. 2000;128(6):895- 902.Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Lüscher TF, Iliceto S, Tona F. Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 2012;126(9):1031-9.McMahon DJ, Carrelli A, Palmeri N, Zhang C, DiTullio M, Silverberg SJ, Walker MD. Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta- Analysis. J Clin Endocrinol Metab. 2015;100(12):4399-407Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol 2011;2011:974647.Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease--a review. Eur Heart J. 2004;25(20):1776-87.Walker MD, Rundek T, Homma S, DiTullio M, Iwata S, Lee JA, Choi J, Liu R, Zhang C, McMahon DJ, Sacco RL, Silverberg SJ. Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol. 2012;167(2):277-85.Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I, Dogan Cakir S, Altuntas Y. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-8.Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55(6):601-6.Cawthon PM, Parimi N, Barrett-Connor E, Laughlin GA, Ensrud KE, Hoffman AR, Shikany JM, Cauley JA, Lane NE, Bauer DC, Orwoll ES, Cummings SR; Osteoporotic Fractures in Men (MrOS) Research Group. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab. 2010;95(10):4625-34Grandi NC, Breitling LP, Hahmann H, Wüsten B, März W, Rothenbacher D, Brenner H. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart. 2011;97(15):1215-21.van Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD, Pilz S, Brouwer IA. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab. 2013;98(4):E638-45.Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, Kapl M, Grammer T, Ritz E, Horina JH, Kleber ME, Pieske B1, Kraigher-Krainer E, Hartaigh BÓ, Toplak H, van Ballegooijen AJ, Amrein K, Fahrleitner-Pammer A, März W. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol. 2015;184:710-6.van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165(5):655-64, 664.e1-5.Yang B, Lu C, Wu Q, Zhang J, Zhao H, Cao Y. Parathyroid hormone, cardiovascular and all-cause mortality: A meta-analysis. Clin Chim Acta. 2016;455:154-60.Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur J Cardiovasc Prev Rehabil. 2004;11(1):69-74.Jassal SK, Chonchol M, von Mühlen D, Smits G, Barrett-Connor E. Vitamin d, parathyroid hormone, and cardiovascular mortality in older adults: the Rancho Bernardo study. Am J Med. 2010;123(12):1114-20.Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011;161(5):956-62.Szulc P, Claustrat B, Delmas PD. Serum concentrations of 17beta-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men--the MINOS study. Clin Endocrinol (Oxf). 2009;71(4):594-602.Lee DM, Vanderschueren D, Boonen S, O’Neill TW, Pendleton N, Pye SR, Ravindrarajah R, Gielen E, Claessens F, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Wu FC; European Male Ageing Study Group. Association of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone with mortality among middle-aged and older European men. Age Ageing. 2014;43(4):528-35Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119-27.Natoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol. 2013;14:88.Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS, Siscovick DS. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58(14):1433-41.Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Arnlöv J. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12(11):1186-92.Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13(6):626-32.Eigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg. 2004;239(4):528-35.Palazzo FF, Delbridge LW. Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism. Surg Clin North Am. 2004;84(3):717-34.Pallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician. 2011;57(2):184-9.Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grübler M, Fahrleitner-Pammer A, Mrak P, Toplak H, Kraigher-Krainer E, März W, Pilz S. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63(1):20-31.Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, Drechsler C, März W, Ofner M, Pieber TR, Pilz S. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012;94(1):10-9.LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bonga.unisimon.edu.co/bitstreams/b8b14705-0e14-44ab-9002-998427063171/download8a4605be74aa9ea9d79846c1fba20a33MD5220.500.12442/1850oai:bonga.unisimon.edu.co:20.500.12442/18502019-04-11 21:51:42.671metadata.onlyhttps://bonga.unisimon.edu.coDSpace UniSimonbibliotecas@biteca.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

Publicaciones similares